Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)

v3.19.3.a.u2
Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Jun. 30, 2019
Total assets $ 133,657 $ 65,147
Contingent consideration 12,555 12,600
Derivative instruments - cash flow hedges 11,273 12,458
Total liabilities 23,828 25,058
Fair Value, Inputs, Level 1 [Member]    
Total assets 128,083 65,147
Contingent consideration 0 0
Derivative instruments - cash flow hedges 0 0
Total liabilities 0 0
Fair Value, Inputs, Level 2 [Member]    
Total assets 5,574 0
Contingent consideration 0 0
Derivative instruments - cash flow hedges 11,273 12,458
Total liabilities 11,273 12,458
Fair Value, Inputs, Level 3 [Member]    
Total assets 0 0
Contingent consideration 12,555 12,600
Derivative instruments - cash flow hedges 0 0
Total liabilities 12,555 12,600
Equity Securities [Member]    
Investments, Fair Value Disclosure [1] 100,006 38,219
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [1] 94,432 38,219
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [1] 5,574 0
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [1] 0 0
Certificates of Deposit [Member]    
Investments, Fair Value Disclosure [2] 33,651 26,928
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [2] 33,651 26,928
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [2] 0 0
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [2] $ 0 $ 0
[1] Included in available-for-sale investments on the condensed consolidated balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) was $11.3 million and $18.8 million as of December 31, 2019 and June 30, 2019, respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $5.6 million as of December 31, 2019. The fair value of the warrant as of June 30, 2019 was not material.
[2] Included in available-for-sale investments on the condensed consolidated balance sheet. The certificate of deposits have contractual maturity dates within one year.